8-K: CV Sciences Reports Mixed Q1 2024 Results: Revenue Slight Dip, Gross Margin Improves, Acquisition Completed

CV Sciences reported a slight revenue decrease but improved gross margins in Q1 2024, alongside the acquisition of Elevated Softgels.

Summary

• CV Sciences reported first quarter 2024 revenue of $4.0 million, a slight decrease from $4.1 million in the same period last year, but a sequential increase from $3.8 million in the previous quarter.
• The company's gross margin improved to 46.3% in Q1 2024, up from 43.0% in Q1 2023 and 45.8% in Q4 2023, marking the best gross margin in the last 12 quarters.
• B2C sales increased by 3% to $1.8 million, while B2B sales decreased by $0.2 million due to lower average order values.
• The total number of units sold decreased by 14.7%, but this was partially offset by an 11.8% increase in average sales prices per unit.
• CV Sciences reported an operating loss of $0.6 million in Q1 2024, compared to an operating income of $5.8 million in Q1 2023, primarily due to a $6.2 million reversal of accrued payroll tax.
• Adjusted EBITDA was negative $0.5 million for Q1 2024, compared to negative $0.2 million in Q1 2023.
• The company's cash balance decreased to $0.7 million at the end of the quarter, down from $1.3 million at the end of 2023.
• CV Sciences completed the acquisition of Elevated Softgels, a manufacturer of encapsulated softgels and tinctures.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While the gross margin improved and an acquisition was completed, the company reported a decrease in revenue, an operating loss, negative adjusted EBITDA, and a decrease in cash balance. The positive aspects are offset by the negative financial results.

Positives

• Gross margin improved to 46.3%, the best in the last 12 quarters.
• B2C sales increased by 3% year-over-year.
• Average sales price per unit increased by 11.8%.
• The company completed the acquisition of Elevated Softgels.
• CV Sciences maintained its position as the top-selling hemp extract brand in the natural product retail sales channel.

Negatives

• Total revenue decreased by 4% year-over-year.
• B2B sales decreased due to lower average order values.
• The total number of units sold decreased by 14.7%.
• The company reported an operating loss of $0.6 million.
• Adjusted EBITDA was negative $0.5 million.
• The cash balance decreased to $0.7 million.

Risks

• The company faces challenges in maintaining revenue growth in a competitive market.
• The decrease in B2B sales and overall unit sales could impact future revenue.
• The company's operating loss and negative adjusted EBITDA raise concerns about profitability.
• The low cash balance could limit the company's ability to invest in growth initiatives.
• The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.

Future Outlook

The company plans to increase the existing business of Elevated Softgels and in-source production of certain key products. They also continue to evaluate merger, sale, acquisition or other options.

Management Comments

• Joseph Dowling, Chief Executive Officer of CV Sciences, stated that they are pleased with their first quarter 2024 results.
• Joseph Dowling noted that the 46.3% gross margin in the first quarter 2024 is their best gross margin in the last 12 quarters.
• Management believes that the first quarter 2024 progress demonstrates their continuous commitment to innovation and cost-efficient execution as they move closer to profitability and positive cash flow.
• Management is thrilled that Elevated Softgels and its employees are joining CV Sciences as another milestone in their transition to a global health and wellness company.

Industry Context

The company operates in the competitive consumer wellness market, specializing in hemp extracts and nutraceuticals. The acquisition of Elevated Softgels is a strategic move to expand manufacturing capabilities and potentially improve margins. The company's focus on science-backed products and clinical research aligns with the growing consumer demand for evidence-based wellness solutions.

Comparison to Industry Standards

• CV Sciences' gross margin of 46.3% is a positive sign, but it is important to compare this to other companies in the nutraceutical and hemp extract space. For example, companies like Charlotte's Web (CWBHF) and Canopy Growth (CGC) have reported varying gross margins, and a detailed comparison would be needed to assess CV Sciences' performance relative to these peers.
• The operating loss of $0.6 million is a concern, and it is important to compare this to the operating performance of similar companies. Many companies in the cannabis and hemp space are still working towards profitability, and CV Sciences' performance needs to be benchmarked against these companies.
• The acquisition of Elevated Softgels is a strategic move, and its impact on the company's financials and operations needs to be monitored. Similar acquisitions in the industry have had varying degrees of success, and it is important to assess how this acquisition will contribute to CV Sciences' long-term growth and profitability.

Stakeholder Impact

• Shareholders may be concerned about the decrease in revenue, operating loss, and negative adjusted EBITDA.
• Employees may be impacted by the acquisition of Elevated Softgels and any potential changes in operations.
• Customers may benefit from the expanded product offerings and improved quality due to the acquisition.
• Suppliers may see changes in demand and procurement practices due to the acquisition.
• Creditors may be concerned about the company's low cash balance and operating losses.

Next Steps

• The company plans to increase the existing business of Elevated Softgels.
• The company intends to in-source production of certain key products.
• The company will continue to evaluate inbound and outbound merger, sale, acquisition or other options.

Key Dates

Keywords

hemp extracts, CBD, nutraceuticals, consumer wellness, financial results, gross margin, EBITDA, acquisition, Elevated Softgels, B2B sales, B2C sales